1 active not recruiting, 1 not yet recruiting, 1 recruiting. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow KN026: new trials by email Literature Review of KN026 trials Research Report on KN026
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer KN026, HB1801, Trastuzumab - Resectable HER2-positive Breast Cancer | Phase 3 | Recruiting | Shanghai JMT-Bio Inc. | 1800 | 2026-03-06 | 2026-04-08 |
| A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer KN026, Capecitabine, Enlonstobart - HER2-positive Gastric Cancer | Phase 2 / Phase 3 | Not yet recruiting | Shanghai JMT-Bio Inc. | 490 | 2025-12-30 | 2026-01-12 |
| A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer KN026, HB1801, Pertuzumab - Early or Locally Advanced HER2-positive Breast Cancer | Phase 3 | Active not recruiting | Shanghai JMT-Bio Inc. | 520 | 2024-12-16 | 2026-07-07 |
China (2)